Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms

Histiocytic neoplasms are a heterogeneous group of clonal hematopoietic disorders marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway.(1,2) For the 50% of histiocytosis patients with BRAFV600-mutations(3–5), RAF inhibition is highly efficacious and has dramatically alt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nature
Main Authors: Diamond, Eli L., Durham, Benjamin H., Ulaner, Gary A, Drill, Esther, Buthorn, Justin, Ki, Michelle, Bitner, Lillian, Cho, Hana, Young, Robert J., Francis, Jasmine H, Rampal, Raajit, Lacouture, Mario, Brody, Lynn A., Ozkaya, Neval, Dogan, Ahmet, Rosen, Neal, Iasonos, Alexia, Abdel-Wahab, Omar, Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6438729/
https://ncbi.nlm.nih.gov/pubmed/30867592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-019-1012-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados